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Background:Oneof themost important organ involvements inpsoriasis is atherosclerotic cardiovascular disease.
Homocysteine is known to have atherogenic properties, but some inconsistency exists in the literature
about its probable role as a risk factor of cardiovascular disorder in patients with psoriasis.
Objective: Because of some controversies, we compared homocysteine levels and related parameters of
metabolic cycles in patients with psoriasis and healthy individuals.
Methods:This case-control studywas conductedon50patientswithpsoriasis and50healthy individuals as
the controls. Serumhomocysteine, vitamin B12 levels, and erythrocyte folate concentrationswere checked
in all participants.
Results:Mean serumhomocysteine, erythrocyte folate, and vitaminB12 levels did not showany significant
difference between the two groups (p N .05), but interestingly, in patientswith psoriasis, men had a signif-
icantlyhigher incidenceofhyperhomocysteinemia and lower levels of erythrocyte folate (p=.14).Overall,
there is no significant difference in serum levels of homocysteine and metabolic-related parameters be-
tween the case and control group. There was no significant relationship between the severity of psoriasis
and the body mass index of patients (p N .05).
Conclusion:Patientswithpsoriasis hadahigherbodymass indexandhigher levels of homocysteine inmen.
Hyperhomocysteinemia could be a predisposing factor of cardiovascular events, butmore evaluations as a
part of metabolic syndrome in patients with psoriasis are needed.
© 2018 Published by Elsevier Inc. on behalf ofWomen's Dermatologic Society. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Psoriasis is well known in the field of dermatology as a common
disorder with a world-wide distributed that presents with long-last-
ing immune system inflammation and many extracutaneous mani-
festations. Because of the chronic inflammatory basis of psoriasis,
many other disorders can be involved, including metabolic syn-
drome, risk of cardiovascular diseases, inflammatory bowel disease,
and even malignancies (Lajevardi et al., 2014; Patel et al., 2011).
Many articles address the association between psoriasis and




Women's Dermatologic Society. Tmedication, such as pioglitazone, in treatment of psoriasis (Neimann
et al., 2006; Ehsani et al., 2016; Hallaji et al., 2016; Lajevardi et al.,
2015). Moreover, psoriasis is recognized as an independent risk fac-
tor with myocardial and cerebral infarction and peripheral vascular
disease, especially moderate-to-severe psoriasis. The risk is more
prominent in young patients, directly related to increased severity
of psoriasis (Patel et al., 2011; Gelfand et al., 2006, 2009; Kimball et
al., 2010).
Given the atherogenic and prothrombotic effects of homocyste-
ine, hyperhomocysteinemia is associated with numerous thrombotic
vascular events (Rosenson et al., 2011). Homocysteine converts to
methionine with vitamin B12 and folate as co-factors of this process.
In the metabolic cycle of homocysteine synthesis, a decrease in vita-
min B12 and folate leads to higher levels of homocysteine and
lower levels of methionine. As proposed in recent studies, the prolif-
eration of epidermal keratinocytes in psoriasis and use of folic acid as
a result may decrease serum folate levels by dividing cells (troughhis is an open access article under the CC BY-NC-ND license (http://creativecommons.
172 R. Abedini et al. / International Journal of Women's Dermatology 5 (2019) 171–174DNA methylation) or impairing intestinal folate absorption after mi-
croscopic inflammatory changes of intestinal mucosa, which leads
to increased levels of serum homocysteine (Malerba et al., 2006a;
McDonald et al., 2012; Tobin et al., 2010).
Findings from several studies have shown that there are some in-
consistencies in hyperhomocysteinemia folate and vitamin B12 levels
in patients with psoriasis and their association with disease severity
(Brazzelli et al., 2010; Cakmak et al., 2009; Gisondi et al., 2010;
Karabudak et al., 2008; Malerba et al., 2006a; McDonald et al., 2012;
Patel et al., 2011; Tobin et al., 2010, 2011; Vanizor Kural et al.,
2003). New investigations confirmhigher serumhomocysteine levels
and related metabolites in the L-arginine-NO pathway (especially
ADMA) and its direct correlation with disease severity (Bilgiç et al.,
2015; Giannoni et al., 2015). However, some studies have not found
any significant difference between serum homocysteine levels in
cases and controls; these studies have introduced other inflamma-
tory mediators, such as sC40L, lipocalin 2, and STNFR-1, as more im-
portant in the pathogenesis of psoriasis (Ataseven et al., 2014;
Erturan et al., 2014).
Therefore, for better management, we designed a comparative
study to analyze serum homocysteine, erythrocyte folate, and vita-
min B12 levels in psoriasis as a case-control study.
Patients and methods
This case-control studywas performed at the Razi Hospital in Teh-
ran, Iran, in 2012. Fifty patients with psoriasis as the case group and
50 healthy individuals as the control group were enrolled in the
study. Ethics approval was obtained from the ethics committee of
the Tehran University of Medical Science, and all patients completed
the informed consent form.
None of the participants were taking supplement therapy. Pa-
tients with plaque type psoriasis whowere not taking systemic ther-
apeutic regimens for psoriasis during the past month were selected
as cases. The controls were selected from consenting age- and sex-
matched healthy individuals who were admitted to the hospital for
cosmetic surgeries with no history of inflammatory skin disorders.
For all participants, chronic liver or kidney disease, hypo- or hyper-
thyroidism, diabetes mellitus, history of vascular events, malignancy,
taking drugs with an effect on serum homocysteine levels (i.e., phe-
nytoin, carbamazepine, penicillamine, theophylline, vitamins, oral
contraceptive pills, azathioprine, metformin, and thiazide diuretics),
and cigarette smoking were considered as the exclusion criteria.
Demographic data of the participants and their body mass index
(BMI; weight [kg]/height [m]2) were recorded, as was the Psoriasis
Area and Severity Index (PASI; Carlin et al., 2004) score for the case
group.
A sample of 4ml of bloodwas taken fromboth groups. The samples
were centrifuged, and total serum homocysteine (free and protein-
bound) levels were measured with the Diazyme Homocystein Assey
kit from Roche Company and read with the Elecsys 2010 and enzyme
colorimetry method. Serum vitamin B12 and erythrocyte folate levels
were measured with Roche kits and the Elecsys 2010 device.
Data was entered in SPSS, version 22, and analyzed. To describe
the quantitative data, mean, median, and standard deviation were
used. T and χ2 tests and Pearson correlation coefficients were used
to compare between two normally distributed qualitative variables;
otherwise, a Spearman correlation test was performed.
Results
Age and sex
The case and control groups were matched for age and sex. The
mean age of patients was 39.2 ± 14.2 years. Fifty-six men and 44women were enrolled in the study. In each group, 28 men (56%)
and 22 women (44%) participated. The overall mean BMI in this
study was 28.5 ± 5.1, and the mean BMI was 29.7 ± 5.3 and 26.9
± 4.4 in the case and control groups, respectively, whichwas statisti-
cally significant (p = .008).
The serumhomocysteine levelswerewithin thenormal range of 5
to 20 μmol/L; overall, the mean serum homocysteine level was 14.2
± 9.8 μmol/L, with 15.15 ± 9.19 μmol/L in the case group and 13.66
± 7.09 μmol/L in the control group and showed no significant differ-
ence (p N .05).
Erythrocyte folate levels werewithin the normal range of 120 to 860
ng/ml, and total mean serum erythrocyte folate level was 343.6± 180.9
ng/ml. The mean serum erythrocyte folate levels were 351.79 ± 235.82
ng/ml and384.30±160.27ng/ml in the caseandcontrol groups, respec-
tively, and the difference was not statistically significant (p N .05).
Serum vitamin B12 levels were within the normal range of 160 to
970 pg/ml. Overall, the mean serum vitamin B12 level was 325.4 ±
278.8 pg/ml. In the case group, the level was 300.16 ± 280.9 pg/ml,
and in the control group it was 370.88 ± 340.97 pg/ml, which was
not statistically significant (p N .05).
The mean range of PASI scores in the case group was 10.4 ± 5.3.
Despite the association between BMI and psoriasis (p = .008),
there was no significant relationship between disease severity
(PASI) and BMI (p N .05). In addition, we found that the BMI of pa-
tients with psoriasis (case group)was higher than that of the controls
(p=.008). 2) Also, in both groups,menhad lower serum folate levels
than women (p = .026).
Vitamin B12 levels had a weak direct relationship with folate
levels, but it was not statistically significant (p = .062; r = .14).
Erythrocyte folate levels in 22% of patients in the case group was
lower than the normal range; however, in all controls, the levels
were normal. Serum homocysteine levels in 22% of the case group
and 24% of the control group exceeded the normal range. Sixteenper-
cent of the case group and 8% of the control group had a vitamin B12
deficiency, but the difference was not statistically significant. Table 1
shows a comparison between the case and control groups with re-
gard to measured variables.
Discussion
Previous studies have provided strong evidence about the role of
homocysteine as an independent risk factor for atherosclerotic vascu-
lar disorders (Bilgiç et al., 2015; Boushey et al., 1995; Clarke et al.,
1991; Cleophas et al., 2000; Fallon et al., 2001; Giannoni et al.,
2015; Vanizor Kural et al., 2003).
According to an increased prevalence of cardiovascular disease and
its association with a higher mortality in patients with psoriasis, deter-
mining relevant risk factors in these patients would be very important
and valuable. Research supports that patients with psoriasis are more
obese than the normal population (Bryld et al., 2010; Duarte et al.,
2010; Herron et al., 2005; Sterry et al., 2007). In addition, a direct corre-
lation between disease severity and obesity has been found (Bryld et al.,
2010;Herron et al., 2005; Langan et al., 2012). In this study, BMIwas sig-
nificantly higher in the case group than in the controls, and although
there was a direct relationship between a higher BMI and the presence
of psoriasis, no significant relationship was found with its severity
(PASI score). These findings ae similar to those by Tobin et al. (2011).
Serum homocysteine levels were not significantly different be-
tween the case and control groups, which was not compatible with
the results of most similar studies that showed higher homocysteine
levels in patients with psoriasis (Bilgiç et al., 2015; Brazzelli et al.,
2010; Giannoni et al., 2015; Gisondi et al., 2010; Karabudak et al.,
2008; Malerba et al., 2006a; Tobin et al., 2011; Vanizor Kural et al.,
2003). Other studies have indicated a direct relationship between ho-
mocysteine levels and the severity of psoriasis; however, in the study
by Cakmak et al. (2009), this direct relationship was not observed,
which is consistent with the results of our study (Ataseven et al.,
2014; Cakmak et al., 2009; Erturan et al., 2014).
In this study, a significant inverse relationship was detected
between homocysteine and vitamin B12 levels that are reasonable
with regard to homocysteine metabolism (Rosenson and Kang,
2011). About relationship between sex and homocysteine and ery-
throcyte folate levels; in both case and control groups; men had
higher homocysteine and lower folate levels. (erythroctye is better
than serum in assessing folate level because it is less affected by
the dietary regimen) (Brazzelli et al., 2010; Cakmak et al., 2009;
Malerba et al., 2006b; McDonald et al., 2012). In both the case
and control groups, men had higher homocysteine and lower folate
levels. Previous studies have not shown any similar relationships,
and these findings could generate the hypothesis that folate defi-
ciency might be a risk factor for increasing homocysteine levels
and cardiovascular events.
Erythrocyte folate levels were not significantly different
between the case and control groups, and only one study
(Cakmak et al., 2009) has reported results similar as ours. Other
studies have mentioned a significant decrease in folate levels in
patients with psoriasis (Brazzelli et al., 2010; Gisondi et al., 2010;
Karabudak et al., 2008; Malerba et al., 2006a; Tobin et al., 2011;
Vanizor Kural et al., 2003).
No significant differences in vitamin B12 levels were revealed in
the case and control groups, which is compatible with the results
by Cakmak et al. (2009) and Malerba et al. (2006a). Other studies,
such as the study by Tobin et al. (2011), demonstrated a significant
difference in vitamin B12 levels in both the case and control
groups. Vitamin B12 levels had a weak direct relationship with
folate levels; however, this was not statistically significant like
the significant relationship between vitamin B12 and folate levels
in many other studies (Brazzelli et al., 2010; Cakmak et al., 2009;
Malerba et al., 2007; McDonald et al., 2012).
Of note, changes in folate levels can be in line with vitamin B12
levels, possibly because of nutritional status (Brazzelli et al., 2010;
Cakmak et al., 2009; Malerba et al., 2007; McDonald et al., 2012). A
study by Tobin et al. (2011) highlighted a relation between BMI
and psoriasis, but not with PASI score. A variety of findings have
been reported by other researchers, such as a significant correla-
tion between homocysteine and folate levels with severity of dis-
ease (Malerba et al., 2007) and between homocysteine levels and
severity of disease (Bilgiç et al., 2015; Cakmak et al., 2009;
Giannoni et al., 2015).
Our results showed that although the difference between mean
folate and vitamin B12 levels in both groups were not statistically
significant, the prevalence of folate and vitamin B12 deficiency
among patients in the case group was higher than that in the con-
trol group (22% of patients and 0% of healthy individuals for folate
levels, and 16% of patients and 8% of healthy individuals for vita-
min B12 levels).
Malerba et al. (2007) reported the percentage of the variables as
follows: 62.5% of patients and 20% of healthy individuals had
hyperhomocysteinemia (unlike in our study), and 32.5% of patients
but none of the controls had folate deficiency (similar to our
study). Additionally, none of the participants had a vitamin B12
deficiency (unlike this study).
Limitations and recommendations
Nutritional issues can influence results (e.g., prevalence of vita-
min deficiencies in different societies), and by increasing the sam-
ple size, we can eliminate the influence of such confounding
factors and discuss significant relationships more confidently.
More accurate studies with larger sample sizes in different groups
of patients with psoriasis that consider other cardiovascular risk
factors should be conducted to confirm the definite role of hyper-
homocysteinemia and folate deficiency in atherosclerotic events.
Conclusions
Although we could not show any significant difference between
the case and control groups with regard to serum homocysteine
levels and related parameters, there was a higher presence of
hyperhomocysteinemia in the male patients with psoriasis.
According to our findings, patients with psoriasis had a higher
BMI, which was not related to their PASI score. Logically, this is a
predisposing factor of cardiovascular events that needs more eval-
uation as part of metabolic syndrome in patients with psoriasis.
Finally, the administration of folic acid and vitamin B12 as a sup-
plement should be studied in patients with high-risk psoriasis as
a preventive strategy.
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